FIELD: medicine.
SUBSTANCE: group of inventions refers to treating fatty liver degeneration. The method of treating a patient suffering fatty liver degeneration involves administering a therapeutically effective amount of cysteamine or cystamine, or a pharmaceutically acceptable salt thereof as a part of a composition. The method of treating the patient suffering non-alcoholic fatty liver degeneration (NAFLD) or non-alcoholic steatohepatitis (HASH) involves administering the therapeutically effective amount of the composition containing cysteamine or cystamine, or the pharmaceutically acceptable salt thereof. In both methods, the composition may be presented by a delayed or controlled release dosage form containing an enteric coating and providing the improved delivery of cysteamine or cystamine, or the pharmaceutically acceptable salt thereof.
EFFECT: improving the method of treating.
24 cl, 3 ex, 7 dwg
| Title |
Year |
Author |
Number |
| METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION AND ISCHEMIC DAMAGE |
2012 |
- Dokhil Randzhan
- Fillips Syuzan A.
|
RU2638807C2 |
| CYSTEAMINE DIOXYGENASE-RESISTANT ANALOGUES OF CYSTEAMINE AND THEIR USE |
2016 |
- Zankel, Todd, C.
- Unitt, John
- Phillips, Timothy
- Gourdet, Benoit
- Duffy, Loma
|
RU2766579C2 |
| USE OF TRIACETYL-3-HYDROXYPHENYLADENOSINE FOR THE PREPARATION OF PHARMACEUTICAL DRUG FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE |
2016 |
|
RU2759916C2 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS |
2017 |
- Nordkild, Peter
- Kjaerulff, Soren
|
RU2740913C2 |
| MATERIALS AND METHODS FOR METABOLISM MODULATION |
2005 |
- Chan' Bill Piu
- Vong Gari Kvan Po
- Sjuj Tszin'Sjan'
- Chi Fransish
|
RU2387445C2 |
| USE OF PEGYLATED RECOMBINANT CHIMERIC MOUSE FIBROBLAST-21 GROWTH FACTOR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT IN COMPOSITION OF DRUGS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
2018 |
- Li, Jian
- Han, Jun
- Ma, Xiaohui
- Tai, Ping
- Wang, Genbei
- Cao, Xiaodan
- Huang, Ruijing
- Jin, Yongjie
- Li, Jing
- Chen, Chen
- Jia, Guoyong
- Wang, Yuanyuan
|
RU2785582C2 |
| COMPOSITION FOR IMPROVING OR PREVENTING NON-ALCOHOLIC FATTY LIVER DYSTROPHY |
2016 |
- Kessoku, Takaomi
- Nakajima, Atsushi
- Sumida, Yoshio
- Eguchi, Yuichiro
- Saito, Susumu
- Sauchi, Yusuke
|
RU2746091C2 |
| METHOD OF TREATING HEPATIC FIBROSES |
2017 |
|
RU2740902C2 |
| PREVENTIVE AND THERAPEUTIC DRUG FOR NON-ALCOHOLIC FATTY LIVER DISEASE |
2018 |
- Sasaki, Yusuke
- Asahiyama, Masato
- Tanaka, Toshiya
|
RU2820552C2 |
| COMBINATION OF OMEGA-3 FATTY ACID AND SGLT-2 INHIBITOR FOR TREATING LIVER DISEASES |
2015 |
- Gannedahl Karl Erik Goeran
|
RU2695652C2 |
